Acuren Corporation Announces Effectiveness of its Registration Statement and Completion of Domestication

Acuren has announced two significant developments: First, the SEC has declared effective its Registration Statement on Form S-4 (File No. 333-282976) as of December 16, 2024.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

12/17/2024 - 07:30 AM

TOMBALL, Texas--(BUSINESS WIRE)-- Acuren Corporation (the “Company”) announces that, effective as of December 16, 2024, its Registration Statement on Form S-4 (File No. 333-282976) has been declared effective by the U.S. Securities and Exchange Commission and it has completed its re-domiciliation from the British Virgin Islands into a Delaware corporation (the “Domestication”). The Company anticipates its common stock will begin trading on the OTC Market prior to the end of the year. The Company intends to apply to list its common stock on the New York Stock Exchange during the first quarter of 2025.

About Acuren:

Acuren is a leading provider of critical asset integrity services. The company operates primarily in North America serving a broad range of industrial markets. It provides these essential and often compliance-mandated (often at customer locations) services in the industrial space and is focused on the recurring maintenance needs of its customers. The work Acuren does fits in the service category referred to as Testing, Inspection and Certification (TIC) including Nondestructive Testing (NDT) in the field and the laboratory and in-lab destructive testing capabilities. More information can be found at https://www.acuren.com/.

Forward-Looking Statements and Disclaimers:

This press release does not constitute or form part of any offer or invitation to purchase, otherwise acquire, issue, subscribe for, sell or otherwise dispose of any securities, nor any solicitation of any offer to purchase, otherwise acquire, issue, subscribe for, sell, or otherwise dispose of any securities of the Company.

This press release contains forward-looking statements which are based on the Company’s expectations, intentions and projections regarding (i) listing on the New York Stock Exchange and (ii) the commencement of trading on the OTC Market. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.